Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Untitled source document

No live link available for this source.

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Global Anomaly Detection Market is projected to reach USD 19.4 Billion by 2031

    80% confidence
  • North America maintains dominance within the anomaly detection market, supported by advanced cybersecurity infrastructure, high enterprise digitalization levels, and early adoption of AI-driven analytics solutions

    80% confidence
  • The Global Anomaly Detection Market was valued at USD 5.66 Billion in 2024

    80% confidence
  • Market expansion is attributed to growing enterprise investments in AI-enabled monitoring systems, expanding application across digital security frameworks, and accelerating demand for automated threat detection solutions

    80% confidence
  • The market will expand at a CAGR of 16.65% during the forecast period from 2024 to 2031

    80% confidence
  • Strict regulatory frameworks governing data usage impose operational challenges for anomaly detection vendors and enterprise adopters

    80% confidence
  • Many enterprises face technical and financial constraints when integrating anomaly detection solutions into fragmented legacy systems

    80% confidence
  • Asia-Pacific is emerging as a high-growth region, fueled by digital transformation, rising cyber risks, and expanding cloud adoption

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com